RBCC Partner Technology Powers Better Models, Better Research

  RBCC Partner Technology Powers Better Models, Better Research  Business Wire  NOKOMIS, Fla. -- October 2, 2013  The international profile of Rainbow Coral Corp.’s (OTCBB: RBCC) partner technology, the Bio-Assembler, continues to rise as the groundbreaking 3D cell culturing device was featured in another new study published in a respected scientific journal.  Recently, researchers from RBCC’s joint venture partner Nano3D Biosciences (n3D) and Rice University published a study in the scientific journal Acta Biomaterialia demonstrating the advantage of its technology in creating multi-type 3D cultures that closely mimic native tissue. The group, led by Prof. K. Jane Grande-Allen, Bioengineering, used n3D's patented Bio-Assembler magnetic levitation technology to build a sub-physiological model of the aortic valve that compared better to the native valve than traditional 2D cultures.  A 3D model that mimics the valve structure could serve as a foundation for groundbreaking cardiovascular research and drug screening—which is why the Bio-Assembler is rapidly gaining in popularity in cellular research labs around the world.  The Bio-Assembler has been the star technology in a number of recent high-profile scientific journal articles, including studies in Nature Reviews Cancer, Nature Protocols and Biophysica Acta. That’s good news for RBCC, which signed a joint venture agreement to help market the technology last year. Widely read by researchers and scientists, these scientific journals have already given the Bio-Assembler a big boost in name recognition among biotech professionals.  Rainbow Biosciences is dedicated to the marketing and development of new medical and research technology innovations designed to help capture a growing share of a booming biotech industry alongside Bristol Myers Squibb Co. (NYSE: BMY), Biogen Idec Inc. (NASDAQ: BIIB), Abbott Laboratories (NYSE: ABT) and Amgen Inc. (NASDAQ: AMGN).  For more information on RBCC’s partnership with n3D and other biotech initiatives, please visit www.rainbowbiosciences.com/investors.html.  About Rainbow Biosciences  Rainbow Biosciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (OTCBB:RBCC). The Company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visitwww.RainbowBioSciences.com. For investment information and performance data on the Company, please visitwww.RainbowBioSciences.com/investors.html.  Notice Regarding Forward-Looking Statements  Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.  Contact:  Rainbow Coral Corp. Patrick Brown, 850-269-7230 President and CEO info@rainbowcoral.com  
Press spacebar to pause and continue. Press esc to stop.